Iron is a vital microelement that plays an important role in plant metabolism. Consuming a large amount of chemical fertilizers increases the risk factors of neoplastic diseases such as heavy metals and harmful components in crops edible parts. Therefore, utilizing novel technologies to increase yields without requiring more chemical fertilizers seems essential. In this regard, nanotechnology holds considerable potentials for creating valuable outputs in agriculture. The effect of nano chelated iron fertilizer, which is synthesized based on novel nanochelating technology, on agronomic traits and yield of rice were evaluated in the present study. A randomized complete block experiment was conducted with 3 replicates. The treatments were: T0 (control), T1 (2.5 g/L foliar application twice at nursery with a one-week interval), T2 (foliar application at tillering + T1), T3 (foliar application at booting + T1), T4 (foliar application at tillering and booting + T1), T5 (8 kg/ha soil application at tillering + T1), T6 (8 kg/ha soil application at booting + T1), T7 (4 kg/ha soil application at tillering + 4 kg/ha soil application at booting + T1). Nano chelated iron fertilizer increased biological yield by 27% and decreased hollow grain number by 254%; in addition, it raised protein content by 13%. This fertilizer also led to increase in nitrogen, phosphorus, potassium, iron and zinc concentrations in white rice by 46%, 43%, 41%, 25% and 50%, respectively. Nanochelating technology can decrease the need for chemical fertilizers; additionally, this technology has the capability to bio-fortify crops with vital micronutrients.

Introduction: Human mesenchymal stem cells (hMSCs) have been approved for therapeutic applications. Despite the advances in this field, in vitro approaches are still required to improve the essential indices that would pave the way to a bright horizon for an efficient transplantation in the future. Nanotechnology could help to improve these approaches. Studies signified the important role of iron in stem cell metabolism and efficiency of copper chelation application for stem cell expansion Methods: For the first time, based on novel Nanochelating technology, we design an iron containing copper chelator nano complex, GFc7 and examined on hMSCs during in vitro expansion. In this study, the hMSCs were isolated, characterized and expanded in vitro in two media (with or without GFc7). Then proliferation, cell viability, cell cycle analysis, surface markers, HLADR, pluripotency genes expression, homing and antioxidative defense at genes and protein expression were investigated. Also we analyzed the spontaneous differentiation and examined osteogenic and lipogenic differentiation. Results: GFc7 affected the expression of key genes, improving both the stemness and fitness of the cells in a precise and balanced manner. We observed significant increases in cell proliferation, enhanced expression of pluripotency genes and homing markers, improved antioxidative defense, repression of genes involved in spontaneous differentiation and exposing the hMSCs to differentiation medium indicated that pretreatment with GFc7 increased the quality and rate of differentiation. Conclusions: Thus, GFc7 appears to be a potential new supplement for cell culture medium for increasing the efficiency of transplantation.

Context: Selenium (Se) is an essential trace element and plays pivotal roles in poultry nutrition. Aims: The present study was designed to compare the impact of dietary supplementation of different sources of Se on growth performance, Se concentration of breast meat, and immune response of broiler chickens. Methods: In total, 300 1-day-old as hatched broilers were randomly allocated to six dietary treatments, with five replicates of 10 birds per each. The experimental diets were as follows: (1) corn–soybean meal-based diet supplemented with 0.30 mg/kg of sodium selenite, (2) basal diet supplemented with 0.30 mg/kg of Se-enriched yeast, and (3–6) basal diet supplemented with 0.15, 0.30, 0.90 and 1.50 mg/kg of nano-Se respectively. Humoral immunity was assessed by antibody titer against a 5% sheep red blood-cell suspension and cellular immunity was measured by administration of phytohaemagglutinin-p at 38 days. Key results: Results indicated that during the periods from 1 to 10 days, from 11 to 24 days, from 25 to 42 days and from 1 to 42 days, average daily gain, average daily feed intake, and feed conversion ratio did not differ among the treatments (P > 0.05). Assessment of orthogonal contrasts at the whole phase of feeding showed that the average daily gain in the broilers fed organic Se was significantly (P < 0.05) higher than that in those fed inorganic Se, as well as nano-Se in comparison to organic Se; such effects were not observed in earlier feeding stages. Se supplementation significantly increased the Se concentration of breast muscle (P < 0.0001). The birds that received 1.50 mg/kg of diet nano-Se showed higher (P < 0.05) total immunoglobulin and IgG titers in primary and secondary immune responses against sheep erythrocytes respectively. Toe web swelling after 24 h and 48 h of receiving phytohaemagglutinin-p was not affected by Se supplementation (P > 0.05). Conclusions: In conclusion, the addition of nano-Se gave better results than did inorganic (sodium selenite) and organic (yeast selenium) forms of Se in performance traits, breast meat Se concentration and antibody response of broilers. Implications: Novel elemental nanometer particulates, including nano-Se, exhibit new characteristics and a different mode of actions in comparison with organic and inorganic forms of Se sources in poultry diets. Inclusion of the nano form of Se in broiler diets and study of productive performance, immunity responses and meat quality leads to improve balanced broiler diets formulation in view of Se.

Background: Currently, the main goal of cancer research is to increase longevity of patients suffering malignant cancers. The promising results of BCc1 in vitro and vivo experiments made us look into the effect of BCc1 nanomedicine on patients with cancer in a clinical trial. Methods: The present investigation was a randomized, double-blind, placebo-controlled, parallel, and multicenter study in which 123 patients (30-to-85-year-old men and women) with metastatic and non-metastatic gastric cancer, in two separate groups of BCc1 nanomedicine or placebo, were selected using a permuted block randomization method. For metastatic and non-metastatic patients, a daily dose of 3000 and 1500 mg was prescribed, respectively. Overall survival (OS) as the primary endpoint and quality of life (measured using QLQ-STO22) and adverse effects as the secondary endpoints were studied. Results: In metastatic patients, the median OS was significantly higher in BCc1 nanomedicine (174 days [95% confidence interval (CI) 82.37–265.62]) than in placebo (62 days [95% CI 0–153.42]); hazard ratio (HR): 0.5 [95% CI 0.25–0.98; p = 0.046]. In non-metastatic patients, the median OS was significantly higher in BCc1 nanomedicine (529 days [95% CI 393.245–664.75]) than in placebo (345 days [95% CI 134.85–555.14]); HR: 0.324 [95% CI 0.97–1.07; p = 0.066]. The QLQ-STO22 assessment showed a mean difference improvement of 3.25 and 2.29 (p value > 0.05) in BCc1 nanomedicine and a mean difference deterioration of − 4.42 and − 3 (p-value < 0.05) in placebo with metastatic and non-metastatic patients, respectively. No adverse effects were observed. Conclusion: The findings of this trial has provided evidence for the potential capacity of BCc1 nanomedicine for treatment of cancer. Trial registration IRCTID, IRCT2017101935423N1. Registered on 19 October 2017, http://www.irct.ir/ IRCT2017101935423N1

Aims: Despite daily increase in diabetic patients in the world, currently approved medications for this disease, at best, only reduce its progression speed. Using novel technologies is a solution for synthetizing more efficient medicines. In the present study, we evaluated anti-diabetic effects of DIBc, a nano metal–organic framework, which is synthetized based on nanochelating technology. Methods: High-fat diet and streptozotocin-induced diabetic rats were treated by DIBc or metformin for 6 weeks. Results: DIBc decreased plasma glucose, triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein compared with diabetic and metformin groups. In DIBc-treated rats, significant homeostasis model assessment of insulin resistance index, malondialdehyde, and tumor necrosis factor-α decrease was observed. H&E staining showed increased islet number and area in DIBc-treated rats compared with diabetic controls. Conclusion: The results showed anti-diabetic effects of nanochelating-based framework. So DIBc, as a nano structure, has the capacity to be evaluated in future studies as a novel anti-diabetic agent.